James Xue
Algemeen Directeur bij CANBRIDGE PHARMACEUTICALS INC.
Vermogen: 2 M $ op 31-05-2024
Actieve functies van James Xue
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Algemeen Directeur | 30-01-2018 | - |
| Voorzitter | 30-01-2018 | - | |
| Oprichter | 30-01-2018 | - | |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Algemeen Directeur | 12-06-2012 | - |
| Voorzitter | 12-06-2012 | - | |
| Oprichter | 12-06-2012 | - | |
| President | 12-06-2012 | - | |
| CANbridge Consulting LLC | Oprichter | - | - |
| President | - | - | |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Directeur/Bestuurslid | - | - |
| President | - | - | |
| Bedrijfssecretaris | - | - | |
| China Alliance For Rare Diseases | Corporate Officer/Principal | - | - |
| Shanghai Foundation For Rare Disease | Corporate Officer/Principal | - | - |
| University of Michigan Medical School | Corporate Officer/Principal | 01-08-2017 | - |
| Peking University Health Science Center | Corporate Officer/Principal | 01-08-2017 | - |
| The BayHelix Group | Corporate Officer/Principal | - | - |
Loopbaan van James Xue
Eerdere bekende functies van James Xue
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van James Xue
| Peking University School of Pharmaceutical Sciences | Undergraduate Degree |
| Brown University | Doctorate Degree |
| University of California | Graduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 9 |
| China | 6 |
| Kaaimaneilanden | 2 |
Operationeel
| Corporate Officer/Principal | 6 |
| Founder | 3 |
| President | 3 |
Sectoraal
| Consumer Services | 7 |
| Health Technology | 5 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Health Technology |
| CANbridge Consulting LLC | |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| China Alliance For Rare Diseases | |
| Shanghai Foundation For Rare Disease | |
| The BayHelix Group |
